GSK Eyes FDA Filing After Immunotherapy Succeeds in Key Rectal Cancer…

GSK's dostarlimab (Jemperli) met primary endpoints in a Phase 2 trial for dMMR rectal cancer, showing sustained complete responses at 12 months and enabling patients to avoid surgery, chemotherapy, and radiation. The company plans FDA filing with expedited review under the National Priority Review Voucher programme. If you're building surgical robotics or rectal cancer diagnostics for traditional pre-operative staging, your market just shrank. GSK's drug now offers a curative path that skips the operating theatre entirely for a defined patient cohort—and has FDA fast-track approval.